Minerva Neurosciences (NASDAQ:NERV) shares rose as much as 160% premarket on Tuesday after announcing financing of as much as $200 million and plans for NDA resubmission of its Schizophrenia drug.
The biopharmaceutical company announced a securities purchase agreement with institutional